About Cellanome
Cellanome offers an automated platform that allows researchers to study individual cell behaviors and interactions under various conditions. This technology enables live cell phenotypic and functional assays, providing detailed insights into how cells respond to different stimuli over time. Unlike traditional methods that focus on bulk responses, Cellanome highlights the unique reactions of individual cells, making it a valuable tool in life sciences and medical research. The company's goal is to enhance research in cell biology by providing a scalable and precise platform that integrates seamlessly into existing workflows.
Foster City, CaliforniaHeadquarters
2020Year Founded
$195.5MTotal Funding
SERIES_BCompany Stage
Biotechnology, HealthcareIndustries
11-50Employees
Benefits
Health Insurance
Stock Options
401(k) Retirement Plan
Flexible Work Hours
Risks
Increased competition in single-cell analysis could impact Cellanome's market share.
Ethical concerns about cellular manipulation may lead to regulatory challenges.
Economic downturns could reduce demand for Cellanome's platform from research institutions.
Differentiation
Cellanome's platform offers unprecedented detail in individual cell behavior analysis.
The company integrates seamlessly into existing workflows, enhancing research without major disruptions.
Cellanome's focus on live cell assays provides a more granular analysis than traditional methods.
Upsides
Rising demand for personalized medicine aligns with Cellanome's focus on individual cell behaviors.
Growing trend in microfluidics enhances Cellanome's scalable solutions for cell biology research.
Collaborations with pharmaceutical companies offer opportunities for joint ventures and technology sharing.
Funding
Total raised$195.52 M
Latest valuation$750.00 M
StageSERIES_B
SERIES A
7/31/2022$30
$150.00 M